Aziyo Biologics Performance
| AZYODelisted Stock | USD 2.44 0.00 0.00% |
The firm shows a Beta (market volatility) of -1.4, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Aziyo Biologics are expected to decrease by larger amounts. On the other hand, during market turmoil, Aziyo Biologics is expected to outperform it. Aziyo Biologics right now shows a risk of 0.0%. Please confirm Aziyo Biologics sortino ratio, as well as the relationship between the semi variance and day median price , to decide if Aziyo Biologics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aziyo Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Aziyo Biologics is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 30.4 M | |
| Free Cash Flow | -22 M |
Aziyo |
Aziyo Biologics Relative Risk vs. Return Landscape
If you would invest 244.00 in Aziyo Biologics on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Aziyo Biologics or generate 0.0% return on investment over 90 days. Aziyo Biologics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Aziyo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aziyo Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aziyo Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aziyo Biologics, and traders can use it to determine the average amount a Aziyo Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| AZYO |
Based on monthly moving average Aziyo Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aziyo Biologics by adding Aziyo Biologics to a well-diversified portfolio.
Aziyo Biologics Fundamentals Growth
Aziyo Stock prices reflect investors' perceptions of the future prospects and financial health of Aziyo Biologics, and Aziyo Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aziyo Stock performance.
| Return On Equity | -7.75 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.50) % | |||
| Current Valuation | 40.69 M | |||
| Shares Outstanding | 11.92 M | |||
| Price To Book | 13.34 X | |||
| Price To Sales | 1.29 X | |||
| Revenue | 49.19 M | |||
| EBITDA | (22.38 M) | |||
| Cash And Equivalents | 16.49 M | |||
| Cash Per Share | 1.21 X | |||
| Total Debt | 34.89 M | |||
| Debt To Equity | 3.50 % | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (21.43 M) | |||
| Earnings Per Share | (2.18) X | |||
| Total Asset | 68.84 M | |||
| Retained Earnings | (137.99 M) | |||
About Aziyo Biologics Performance
By examining Aziyo Biologics' fundamental ratios, stakeholders can obtain critical insights into Aziyo Biologics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Aziyo Biologics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic devicecardiovascular, orthopedicspinal repair, and soft tissue reconstruction markets. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland. Aziyo Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 162 people.Things to note about Aziyo Biologics performance evaluation
Checking the ongoing alerts about Aziyo Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aziyo Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aziyo Biologics is not yet fully synchronised with the market data | |
| Aziyo Biologics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 49.19 M. Net Loss for the year was (32.9 M) with profit before overhead, payroll, taxes, and interest of 19.22 M. | |
| Aziyo Biologics currently holds about 16.49 M in cash with (21.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21. | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Aziyo Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aziyo Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Aziyo Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aziyo Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aziyo Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aziyo Biologics' stock. These opinions can provide insight into Aziyo Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Aziyo Stock
If you are still planning to invest in Aziyo Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aziyo Biologics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |